Resapp Health Ltd: A speculative stock you should keep your eye on

Resapp Health Ltd (ASX: RAP) is an upcoming mobile phone application, which aims to develop a digital healthcare app that can diagnose patients without them having to visit the doctor. The company’s aim is to provide telehealth companies with point of care services that they can integrate into their platforms to make their clients lives simpler.

ResApp has yet to prove the viability of their technology and their prior clinical study earlier this year had to be thrown out as a result of poor data. The company is now trying to redo its clinical studies and ensure that it can effectively receive approval to use its technology to diagnose patients across the world. Should the company prove successful, the current value of its stock may well shoot upward in value.

Investors who have some spare cash may find ResApp a company worth considering. The company has enormous growth potential and the ability to take advantage of the trend toward technology in the healthcare, if they can execute. If you believe the management, the blotched trial is simply a minor setback.

There are no guarantees however; that the company’s technology will ever be completely licensed and there is a risk the equity will become worthless.

3 Growth Shares To Buy In April

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2018."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor mpinto has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.